340 related articles for article (PubMed ID: 30962581)
1. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.
Bewersdorf JP; Zeidan AM
Leukemia; 2019 Jun; 33(6):1303-1312. PubMed ID: 30962581
[TBL] [Abstract][Full Text] [Related]
2. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
3. Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.
Komrokji RS
Curr Hematol Malig Rep; 2019 Aug; 14(4):346-351. PubMed ID: 31203517
[TBL] [Abstract][Full Text] [Related]
4. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
Zhou L; McMahon C; Bhagat T; Alencar C; Yu Y; Fazzari M; Sohal D; Heuck C; Gundabolu K; Ng C; Mo Y; Shen W; Wickrema A; Kong G; Friedman E; Sokol L; Mantzaris I; Pellagatti A; Boultwood J; Platanias LC; Steidl U; Yan L; Yingling JM; Lahn MM; List A; Bitzer M; Verma A
Cancer Res; 2011 Feb; 71(3):955-63. PubMed ID: 21189329
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Chan O; Komrokji RS
Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
[TBL] [Abstract][Full Text] [Related]
6. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
7. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
Feld J; Navada SC; Silverman LR
Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
[TBL] [Abstract][Full Text] [Related]
8. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
9. Signal transduction inhibitors in treatment of myelodysplastic syndromes.
Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A
J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999
[TBL] [Abstract][Full Text] [Related]
10. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
[TBL] [Abstract][Full Text] [Related]
11. Next-generation therapy for lower-risk MDS.
Sébert M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
[TBL] [Abstract][Full Text] [Related]
12. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A; Hermine O; Platzbecker U
Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Parisi S; Finelli C; Fazio A; De Stefano A; Mongiorgi S; Ratti S; Cappellini A; Billi AM; Cocco L; Follo MY; Manzoli L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467674
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
[TBL] [Abstract][Full Text] [Related]
15. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
16. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes with ring sideroblasts.
Bruzzese A; Vigna E; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Barbato A; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M
Hematol Oncol; 2023 Oct; 41(4):612-620. PubMed ID: 36794650
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
20. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
